Financials data is unavailable for this security.
View more
Year on year Kringle Pharma Inc grew revenues 15.58% from 69.25m to 80.04m while net income improved from a loss of 854.15m to a smaller loss of 756.45m.
Gross margin | -- |
---|---|
Net profit margin | -945.12% |
Operating margin | -1,021.87% |
Return on assets | -28.14% |
---|---|
Return on equity | -36.63% |
Return on investment | -30.03% |
More ▼
Cash flow in JPYView more
In 2024, Kringle Pharma Inc did not generate a significant amount of cash. Cash Flow from Financing totalled 838.23m or 1,047.29% of revenues. In addition the company used 661.17m for operations while cash used for investing totalled 121.36m.
Cash flow per share | -82.31 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 309.55 |
---|---|
Tangible book value per share | 309.55 |
More ▼
Balance sheet in JPYView more
Current ratio | 21.50 |
---|---|
Quick ratio | 19.20 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼